Status:
UNKNOWN
GENOMED4ALL: Improving MDS Classification and Prognosis by AI
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Brief Summary
Myelodysplastic syndromes (MDS) typically occur in elderly people. Current disese classifcation system and prognostic scores (International Prognostic Scoring System, IPSS) present limitations and in ...
Detailed Description
Myelodysplastic syndromes (MDS) typically occur in elderly people. Patients present peripheral blood cytopenia, and with time a portion of these subjects evolve into acute myeloid leukaemia (AML). The...
Eligibility Criteria
Inclusion
- Patients affected by MDS according WHO criteria \> 18 years old
- Avaliability of clinical and hematological information
- Availability of information on targeted mutation screening
Exclusion
- none of the above
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
13284 Patients enrolled
Trial Details
Trial ID
NCT04889729
Start Date
March 15 2021
End Date
December 31 2024
Last Update
September 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Milan, Italy